Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen

Infection and Immunity

Volumn 77, Issue 11, 2009, Pages 4859-4867

  Kelly Cirino, Cassandra D ^b   Mantis, Nicholas J ^a  

^a WADSWORTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX PROTECTIVE ANTIGEN; ANTHRAX TOXIN; CAPILLARY MORPHOGENESIS PROTEIN 2; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1 F1; MONOCLONAL ANTIBODY 14B7; MONOCLONAL ANTIBODY 2 B12; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ANTHRAX; ARTICLE; B LYMPHOCYTE; BINDING SITE; CONTROLLED STUDY; FEMALE; HYBRIDOMA CELL CULTURE; IMMUNIZATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

EID: 70350463878     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00117-09     Document Type: Article

References (46)

1. Abboud, N., and A. Casadevall. 2008. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin. Vaccine Immunol. 15:1115-1123.
2. Alfthan, K. 1998. Surface plasmon resonance biosensors as a tool in antibody engineering. Biosensors Bioelectronics 13:653-663. (Pubitemid 28500056)
3. Anonymous. 2002. The anthrax vaccine: is it safe? Does it work? Institute of Medicine, National Academy Press, Washington, DC.
4. Benson, E. L., P. D. Huynh, A. Finkelstein, and R. J. Collier. 1998. Identi- fication of residues lining the anthrax protective antigen channel. Biochemistry 37:3941-3948.
5. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229.
6. Bradley, K. A., and J. A. Young. 2003. Anthrax toxin receptor proteins. Biochem. Pharmacol. 65:309-314.
7. Brey, R. N. 2005. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 57:1266-1292.
8. Brossier, F., M. Levy, A. Landier, P. Lafaye, and M. Mock. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
9. Campbell, J. D., K. H. Clement, S. S. Wasserman, S. Donegan, L. Chrisley, and K. L. Kotloff. 2007. Safety, reactogenicity, and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccines 3:205-211. (Pubitemid 47598179)
10. Chen, Z., M. Moayeri, Y. H. Zhou, S. Leppla, S. Emerson, A. Sebrell, F. Yu, J. Svitel, P. Schuck, M. St. Clair, and R. Purcell. 2006. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193:625-633.
11. Cirino, N. M., D. Sblattero, D. Allen, S. R. Peterson, J. D. Marks, P. J. Jackson, A. Bradbury, and B. E. Lehnert. 1999. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect. Immun. 67:2957-2963.
12. Collier, R. J., and J. A. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
13. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
14. Fasanella, A., F. Tonello, G. Garofolo, L. Muraro, A. Carattoli, R. Adone, and C. Montecucco. 2008. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use. Vaccine 26:5684-5688.
15. Gauthier, Y. P., J.-N. Tournier, J.-C. Paucod, J.-P. Corre, M. Mock, P. L. Goossens, and D. R. Vidal. 2008. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect. Immun. 77:1197-1207.
16. Grabenstein, J. D. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46:129-136.
17. Gubbins, M. J., J. D. Berry, C. R. Corbett, J. Mogridge, X. Y. Yuan, L. Schmidt, B. Nicolas, A. Kabani, and R. S. Tsang. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47:436-443.
18. Kelly, C. D., C. O'Loughlin, F. B. Gelder, J. W. Peterson, L. E. Sower, and N. M. Cirino. 2007. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J. Immune Based Ther. Vaccines 5:11.
19. Lacy, D. B., D. J. Wigelsworth, H. M. Scobie, J. A. Young, and R. J. Collier. 2004. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 101:6367-6372.
20. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
21. Leppla, S. H., J. B. Robbins, R. Schneerson, and J. Shiloach. 2002. Development of an improved vaccine for anthrax. J. Clin. Investig. 110:141-144.
22. Leysath, C. E., A. F. Monzingo, J. A. Maynard, J. Barnett, G. Georgiou, B. L. Iverson, and J. D. Robertus. 2009. Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J. Mol. Biol. 387:680-693.
23. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
24. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt. 3):707-715.
25. Marvaud, J. C., T. Smith, M. L. Hale, M. R. Popoff, L. A. Smith, and B. G. Stiles. 2001. Clostridium perfringens Iota toxin: mapping of receptor binding and Ia docking domains on Ib. Infect. Immun. 69:2435-2441.
26. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
27. Miller, C. J., J. L. Elliott, and R. J. Collier. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38:10432-10441. (Pubitemid 129515383)
28. Mogridge, J., M. Mourez, and R. J. Collier. 2001. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J. Bacteriol. 183:2111-2116. (Pubitemid 32229126)
29. Mohamed, N., J. Li, C. S. Ferreira, S. F. Little, A. M. Friedlander, G. L. Spitalny, and L. S. Casey. 2004. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72:3276-3283.
30. Molloy, S. S., P. A. Bresnahan, S. H. Leppla, K. R. Klimpel, and G. Thomas. 1992. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem. 267:16396-16402.
31. Neuman de Vegvar, H. E., and W. H. Robinson. 2004. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111:196-201.
32. Nguyen, M. L., S. R. Crowe, S. Kurella, S. Teryzan, B. Cao, J. D. Ballard, J. A. James, and A. D. Farris. 2009. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect. Immun. 77:162-169.
33. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346-11350.
34. Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385: 833-838. (Pubitemid 27106075)
35. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
36. Rivera, J., A. Nakouzi, N. Abboud, E. Revskaya, D. Goldman, R. J. Collier, E. Dadachova, and A. Casadevall. 2006. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 74:4149-4156.
37. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and S. H. Leppla. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944.
38. Santelli, E., L. A. Bankston, S. H. Leppla, and R. C. Liddington. 2004. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 430:905-908. (Pubitemid 39119219)
39. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497.
40. Sivasubramanian, A., J. A. Maynard, and J. J. Gray. 2008. Modeling the structure of MAb 14B7 bound to the anthrax protective antigen. Proteins 70:218-230.
41. Staats, H. F., S. M. Alam, R. M. Scearce, S. M. Kirwan, J. X. Zhang, W. M. Gwinn, and B. F. Haynes. 2007. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 75:5443-5452.
42. Swearengen, J. R. 2005. Biodefense: research methodologies and animal models. CRC Press, Inc., Boca Raton, FL.
43. Varughese, M., A. V. Teixeira, S. Liu, and S. H. Leppla. 1999. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67:1860-1865.
44. Zarebski, L. M., K. Vaughan, J. Sidney, B. Peters, H. Grey, K. D. Janda, A. Casadevall, and A. Sette. 2008. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev. Vaccines 7:55-74.
45. Zhang, J., J. Xu, G. Li, D. Dong, X. Song, Q. Guo, J. Zhao, L. Fu, and W. Chen. 2006. The 2 2-2 3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem. Biophys. Res. Commun. 341:1164-1171.
46. Zhou, B., C. Carney, and K. D. Janda. 2008. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg. Med. Chem. 16:1903-1913.